What Happened
US Food and Drug Administration inspectors documented severe sanitation failures at two Chinese factories producing active ingredients for compounded GLP-1 medications, according to inspection records released under the Freedom of Information Act.
The reports describe black mold growing on manufacturing equipment at one facility and "gross contamination" across production floors. At the same site, inspectors watched employees attempt to hide paperwork and pour out product samples as officials approached. At the second plant, investigators found evidence of fabricated documentation in batch records.
Both facilities make semaglutide and tirzepatide — the two most widely compounded GLP-1 ingredients in the United States, where demand for weight-loss injections has repeatedly outrun brand-name supply.
Who Is Affected
- Compounding pharmacies and telehealth suppliers that source semaglutide or tirzepatide API from Chinese manufacturers
- US consumers of compounded GLP-1 injections, who almost never see which facility produced the ingredient inside their vial
- Researchers buying research-grade peptides, since the same export manufacturing ecosystem supplies both clinical compounding and the gray-market research chemical trade
Timeline
- September 2025: FDA moved to block GLP-1 active ingredients from unverified foreign sources, building an import-alert screening list for ingredient makers
- Since then: FDA has run on-site inspections and remote regulatory assessments of dozens of GLP-1 API sites connected to the US supply chain
- October 2026: The inspection findings — black mold, pest activity, hidden records, and suspect paperwork — surface through a Freedom of Information Act request
- What's next: Facilities that fail inspection can be removed from eligibility lists, and future shipments can be detained at the border
What This Means for Researchers
The findings undercut a common assumption: that a manufacturer's appearance on a regulatory registration list is itself evidence of quality. FDA's own inspection record shows registered sites can still harbor conditions that would disqualify them from supplying US compounding — mold on equipment, pests in production areas, and staff interfering with inspections.
The practical lesson for anyone sourcing peptides is that paperwork provenance and physical manufacturing conditions are separate questions, and only the second determines whether a product is safe to handle. Batch documentation from a compromised facility cannot be treated as reliable evidence of what is in the vial.
How to Verify Your Peptides
Independent laboratory verification remains the strongest defense against contaminated or mislabeled material:
- Our semaglutide purity testing guide covers HPLC purity and identity checks
- Our tirzepatide HPLC testing guide explains the analytical methods involved
- A full walkthrough is in how testing works
Safe Alternatives
- Read our semaglutide compound page and tirzepatide overview for background on these ingredients
- Browse the peptides directory and vetted vendor listings before purchasing anything
Sources
Regulatory inspection records obtained under the Freedom of Information Act; regulatory announcements concerning GLP-1 ingredient import controls.